Skip to main content
. Author manuscript; available in PMC: 2015 Mar 17.
Published in final edited form as: J Psychopharmacol. 2012 Oct 31;27(2):192–202. doi: 10.1177/0269881112464828

Figure 2.

Figure 2

Ability of test compounds to block U50,488–induced antinociception in the tail-withdrawal test. Mice received a single injection of saline, norBNI, 5’-AMN, or 5’-MABN at doses of 1 mg/kg (A), 3.2 mg/kg (B) or 10 mg/kg (C) and tail-withdrawal latency measured up to 35 days post-injection. The data at 7d post-injection shows the dose-dependency of antagonism of U50,488-induced antinociception (D). Data are expressed as mean percent maximum possible effect (%MPE) ± SEM, n = 4–8 per treatment group. Comparison to U50,488 + saline: ### P< 0.001. Comparison to 1mg/kg test compound: * P<0.05 , *** P< 0.001.